IBIO
$2.46
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space.
Intraday
Recent News
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy?
CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
iBio, Inc. (IBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
iBio (IBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
iBio Insiders Placed Bullish Bets Worth US$655.0k
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...
BC-Most Active Stocks
Nu Holdings Ltd. 30,054,902 16.85
iBio, Inc. (IBIO) Reports Q1 Loss
iBio (IBIO) delivered earnings and revenue surprises of -57.14% and 0.00%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?